Phellodendron and Citrus extracts benefit joint health in osteoarthritis patients: A pilot, double-blind, placebo-controlled study

Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I, Cameroon.
Nutrition Journal (Impact Factor: 2.6). 09/2009; 8(1):38. DOI: 10.1186/1475-2891-8-38
Source: PubMed


The objective of this clinical study was to assess the potential benefit of a dietary supplement, NP 06-1, on joint health in overweight and normal weight adults diagnosed with osteoarthritis.
An 8-week placebo-controlled, randomized, double-blind study was conducted with four groups comparing the effects of NP 06-1 to placebo on overweight and normal weight subjects diagnosed with primary osteoarthritis of the knee. NP 06-1 (a combination of two botanical extracts; Phellodendron amurense bark and Citrus sinensis peel) or matching placebo were given in a dose of two capsules (370 mg each) twice daily. The outcome measures were the Lequesne Algofunctional Index (LAI) for joint pain and movement as well as biomarkers of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]).
Eighty (80) subjects were enrolled and 45 subjects completed the study. No serious adverse events were reported. The mean total LAI scores at baseline for the four groups ranged from 11.4 to 12.4 (SD 1.2 to 2.4). Treatment for 8 weeks resulted in a statistical improvement in the LAI score in the overweight treatment group compared to placebo (6.3 +/- 2.3 vs 11.8 +/- 1.5; p < 0.0001). At 8 weeks, a similar result was observed in the normal weight groups (7.7 +/- 1.4 vs 9.9 +/- 0.9; p < 0.0001). There was a reduction in CRP levels with treatment in the overweight treatment group at 8 weeks (-0.62 +/- 0.2; 49%) compared to baseline (p < 0.001) and to placebo (p < 0.001). For the normal weight participants, there were significant reductions in CRP compared to baseline, but not to the matched placebo group. Both overweight and normal weight treatment groups lost a significant amount of weight compared to their placebo groups. The overweight treatment group lost an average of 5% body weight after 8 weeks. There was no significant change in ESR in any of the groups.
In this pilot study, NP 06-1 had beneficial effects on symptoms of osteoarthritis of the knee as measured using LAI scores and had anti-inflammatory effects as measured using CRP. Administration of NP 06-1 was also associated with weight loss, which may have been a contributing factor to the other benefits.

Download full-text


Available from: Julius Oben,
  • Source
    • "Instaflex (3 capsules daily portion) combines 1500 mg of glucosamine sulfate, 500 mg methylsufonlylmethane, and 4 mg hyaluronic acid with several anti-inflammatory substances including white willow bark extract, ginger root concentrate, boswella serrata extract, turmeric root extract, and cayenne. Other combinations of nutraceuticals, botanicals, and dietary supplements that have shown efficacy in reducing joint pain symptoms in double-blind, placebo-controlled studies include Phellodendron amurense bark and Citrus sinensis peel extracts standardized to berberine and polymethoxylated flavones [30], lemon verbena extract (14% verbascoside) with fish oil [31], a product containing dried extracts from six Asian herbs [32], and a mixture of glucosamine, chondroitin, and quercetin glycoside [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to assess the effect of 8-weeks ingestion of a commercialized joint pain dietary supplement (InstaflexTM Joint Support, Direct Digital, Charlotte, NC) compared to placebo on joint pain, stiffness, and function in adults with self-reported joint pain. InstaflexTM is a joint pain supplement containing glucosamine sulfate, methylsufonlylmethane (MSM), white willow bark extract (15% salicin), ginger root concentrate, boswella serrata extract (65% boswellic acid), turmeric root extract, cayenne, and hyaluronic acid. Subjects included 100 men and women, ages 50-75 years, with a history (>3 months) of joint pain, and were randomized to InstaflexTM or placebo (3 colored gel capsules per day for 8 weeks, double-blind administration). Subjects agreed to avoid the use of non-steroidal anti-inflammatory drugs (NSAID) and all other medications and supplements targeted for joint pain. Primary outcome measures were obtained pre- and post-study and included joint pain severity, stiffness, and function (Western Ontario and McMaster Universities [WOMAC]), and secondary outcome measures included health-related quality of life (Short Form 36 or SF-36), systemic inflammation (serum C-reactive protein and 9 plasma cytokines), and physical function (6-minute walk test). Joint pain symptom severity was assessed bi-weekly using a 12-point Likert visual scale (12-VS). Joint pain severity was significantly reduced in InstaflexTM compared to placebo (8-week WOMAC, [downwards arrow]37% versus [downwards arrow]16%, respectively, interaction effect P = 0.025), with group differences using the 12-VS emerging by week 4 of the study (interaction effect, P = 0.0125). Improvements in ability to perform daily activities and stiffness scores in InstaflexTM compared to placebo were most evident for the 74% of subjects reporting knee pain (8-week WOMAC function score, [downwards arrow]39% versus [downwards arrow]14%, respectively, interaction effect P = 0.027; stiffness score, [downwards arrow]30% versus [downwards arrow]12%, respectively, interaction effect P = 0.081). Patterns of change in SF-36, systemic inflammation biomarkers, and the 6-minute walk test did not differ significantly between groups during the 8-week study CONCLUSIONS: Results from this randomized, double blind, placebo-controlled community trial support the use of the InstaflexTM dietary supplement in alleviating joint pain severity in middle-aged and older adults, with mitigation of difficulty performing daily activities most apparent in subjects with knee pain.Trial registration: Identifier: NCT01956500.
    Nutrition Journal 11/2013; 12(1):154. DOI:10.1186/1475-2891-12-154 · 2.60 Impact Factor
  • Source
    • "blend of extracts of Phellodendron amurense tree bark and Citrus sinensis peel, was examined in one trial (Oben et al., 2009). Patients were instructed to take NP 06-1 orally in a dose of 1480 mg/day. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Knee osteoarthritis is the most common form of joint disease and is a major cause of pain and physical disability among the elderly. Although, numerous treatments have been developed to treat osteoarthritis, no definitive treatments with high efficacy and low risk have been identified until now. In recent years, it has been reported that nutraceuticals may be good candidates for the management of knee osteoarthritis. This paper describes the efficacy of nutraceuticals for treating knee osteoarthritis in terms of pain and structural change. To accomplish this, this paper reports on the analysis of randomized, placebo-controlled, clinical trials that were published prior to December 2011.
    AFRICAN JOURNAL OF BIOTECHNOLOGY 02/2012; 11(12). · 0.57 Impact Factor
  • Source
    • "A few plant groups have been studied more in depth. Rutacea (Citrus spp.) have proven anti-inflammatory (Sood et al., 2009; Oben et al., 2009; Vafeiadou et al., 2009; Ghanim et al., 2010), as did Gardenia sp. (Koo et al., 2006; Oh et al., 2006), while many species of Smilax exhibit immuno-modulatory "
    [Show abstract] [Hide abstract]
    ABSTRACT: A total of 96 plant species belonging to 84 genera and 46 families were documented and identified as anti-infective herbal remedies in Northern Peru. Most species used were Asteraceae (18 species, 18.95%), followed by Fabaceae and Euphorbiaceae (7.37% and 5.26%). The most important anti-infectious families are somewhat over-represented in comparison to the overall medicinal flora, while some other medicinally important families (e.g. Lycopodiaceae, Cucurbitaceae) are completely missing from the anti-infective portfolio. The majority of herbal preparations were prepared from the leaves of plants (31.34%), while the whole plant (18.66%), flowers (12.69%) and stems (17.16%) were used less frequently. In almost 67% of the cases fresh plant material was used to prepare remedies. Only about 55% of the remedies were applied orally, while the remaining ones were applied topically. Over half of all remedies were prepared as mixtures of multiple ingredients. The information gained on frequently used traditional remedies against infectious disease agents might give some leads for future targets for further analysis in order to develop new drugs. However, more detailed scientific studies are needed to evaluate the efficacy and safety of the remedies employed traditionally.
    Journal of medicinal plant research 05/2011; 5(8):1297-1304. · 0.88 Impact Factor
Show more